Payment overview · 2025
General Payments
$267.36
15 reported records · 8 companies
Healthcare provider profile · identity verified
Ryan Martinez, MD, MPH
Allopathic & Osteopathic Physicians|Internal Medicine · TUCSON, AZ · NPI 1043623184
Verified facts
What the public records show
CMS Open Payments records show Ryan Martinez, MD, MPH received $267.36 in general payments during 2025 across 15 reported records.
Abbott Laboratories accounted for 26.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $71.00 | 26.6% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $47.05 | 17.6% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $46.65 | 17.4% | 3 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $30.30 | 11.3% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $20.90 | 7.8% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $19.33 | 7.2% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $17.78 | 6.7% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.35 | 5.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $267.36 | 15 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $71.00 | 4 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $46.65 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $33.31 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $33.31 | 2 | 2025 |
Source payment records
|
|||||
| SAPIEN 3 Ultra RESILIA Normalized: sapien 3 ultra resilia |
Device | Edwards Lifesciences Corporation | $30.30 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $20.90 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $20.90 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $19.33 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $17.78 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.35 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $13.74 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $13.74 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
37 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 375 | 111 |
| Atorvastatin Calcium | Atorvastatin Calcium | 355 | 117 |
| Losartan Potassium | Losartan Potassium | 258 | 86 |
| Lisinopril | Lisinopril | 241 | 71 |
| Amlodipine Besylate | Amlodipine Besylate | 239 | 75 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 220 | 74 |
| Metformin Hcl | Metformin Hcl | 186 | 59 |
| Omeprazole | Omeprazole | 165 | 54 |
| Simvastatin | Simvastatin | 146 | 45 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 139 | 50 |
| Gabapentin | Gabapentin | 135 | 51 |
| Tamsulosin Hcl | Tamsulosin Hcl | 127 | 44 |
| Trazodone Hcl | Trazodone Hcl | 120 | 32 |
| Zolpidem Tartrate | Zolpidem Tartrate | 104 | 41 |
| Alprazolam | Alprazolam | 102 | 32 |
| Hydrochlorothiazide | Hydrochlorothiazide | 101 | 32 |
| Oxycodone Hcl | Oxycodone Hcl | 101 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 100 | 29 |
| Duloxetine Hcl | Duloxetine Hcl | 94 | 27 |
| Eliquis | Apixaban | 93 | 30 |
| Metoprolol Succinate | Metoprolol Succinate | 93 | 29 |
| Fluticasone Propionate | Fluticasone Propionate | 84 | 32 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 75 | 18 |
| Pantoprazole Sodium | Pantoprazole Sodium | 73 | 30 |
| Clonazepam | Clonazepam | 72 | 17 |
| Montelukast Sodium | Montelukast Sodium | 69 | 23 |
| Sertraline Hcl | Sertraline Hcl | 69 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 64 | 20 |
| Metoprolol Tartrate | Metoprolol Tartrate | 61 | 21 |
| Ozempic | Semaglutide | 57 | 15 |
| Potassium Chloride | Potassium Chloride | 57 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 56 | 16 |
| Estradiol | Estradiol | 55 | 26 |
| Furosemide | Furosemide | 54 | 22 |
| Sumatriptan Succinate | Sumatriptan Succinate | 54 | 12 |
| Azithromycin | Azithromycin | 46 | 37 |
| Celecoxib | Celecoxib | 46 | 12 |
| Acyclovir | Acyclovir | 45 | 19 |
| Tramadol Hcl | Tramadol Hcl | 44 | 19 |
| Allopurinol | Allopurinol | 43 | 17 |
| Ezetimibe | Ezetimibe | 43 | 14 |
| Pregabalin | Pregabalin | 43 | 11 |
| Carvedilol | Carvedilol | 42 | 13 |
| Xarelto | Rivaroxaban | 42 | suppressed |
| Fluconazole | Fluconazole | 41 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 37 | 19 |
| Diazepam | Diazepam | 37 | 11 |
| Meloxicam | Meloxicam | 37 | 16 |
| Mounjaro | Tirzepatide | 37 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 37 | 11 |
| Finasteride | Finasteride | 36 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 36 | 13 |
| Synthroid | Levothyroxine Sodium | 36 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 35 | 12 |
| Valacyclovir | Valacyclovir Hcl | 35 | 15 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 33 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 31 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 30 | 13 |
| Prednisone | Prednisone | 30 | 16 |
| Metformin Hcl Er | Metformin Hcl | 28 | suppressed |
| Atenolol | Atenolol | 27 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 27 | suppressed |
| Famotidine | Famotidine | 26 | 11 |
| Glipizide Er | Glipizide | 26 | suppressed |
| Lorazepam | Lorazepam | 26 | suppressed |
| Topiramate | Topiramate | 26 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 25 | 21 |
| Tizanidine Hcl | Tizanidine Hcl | 25 | suppressed |
| Irbesartan | Irbesartan | 24 | suppressed |
| Mirtazapine | Mirtazapine | 24 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 24 | 16 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 23 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 23 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 23 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 22 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 21 | 19 |
| Methocarbamol | Methocarbamol | 21 | suppressed |
| Chlorthalidone | Chlorthalidone | 20 | suppressed |
| Ibuprofen | Ibuprofen | 20 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 19 | 19 |
| Temazepam | Temazepam | 19 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 18 | 11 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 18 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 18 | suppressed |
| Spironolactone | Spironolactone | 18 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 17 | suppressed |
| Bupropion Xl | Bupropion Hcl | 17 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 17 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Lovastatin | Lovastatin | 17 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 17 | suppressed |
| Carisoprodol | Carisoprodol | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 16 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 16 | suppressed |
| Myrbetriq | Mirabegron | 16 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 15 | suppressed |
| Glipizide | Glipizide | 15 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | 14 |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Nystatin | Nystatin | 15 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 15 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Methylprednisolone | Methylprednisolone | 14 | 12 |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Ciclopirox | Ciclopirox | 13 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 12 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | suppressed |
| Glimepiride | Glimepiride | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 12 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Trulicity | Dulaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $267.36 · 15 records | Abbott Laboratories | AIRSUPRA, CAPVAXIVE, Cologuard Collection Kit, EVENITY, FREESTYLE LIBRE 3, GARDASIL 9, MOUNJARO, OTEZLA, PROLIA, REPATHA, SAPIEN 3 Ultra RESILIA, SHINGRIX | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error